Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro
Open Access
- 1 October 2002
- journal article
- other
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (10) , 870-876
- https://doi.org/10.1136/ard.61.10.870
Abstract
Background: Interleukin 17 (IL17) is produced by activated T cells and has been implicated in the development of bone lesions and cartilage degradation in rheumatoid arthritis (RA). Objective: To determine whether IL17, alone or together with tumour necrosis factor α (TNFα), induces cartilage destruction in vitro. Methods: Fetal mouse metatarsals stripped of endogenous osteoclast precursors were used to study the effect of IL17 on cartilage degradation independently of osteoclastic resorption. Cartilage destruction was analysed histologically by Alcian blue staining. Results: IL17 alone, up to 100 ng/ml, had no effect on the cartilage of fetal mouse metatarsals. IL17 (≥0.1 ng/ml), however, induced severe cartilage degradation when given together with TNFα (≥1 ng/ml). The cytokine combination decreased Alcian blue staining, a marker of proteoglycans, throughout the metatarsals and induced loss of the proliferating and early hypertrophic chondrocyte zones. TNFα alone also decreased Alcian blue staining, but not as dramatically as the cytokine combination. In addition, it did not induce loss of chondrocyte zones. Treatment with inhibitors of matrix metalloproteinase (MMP) activity and nitric oxide synthesis showed that MMP activity played a part in cartilage degradation, whereas nitric oxide production did not. Conclusions: IL17, together with TNFα, induced cartilage degradation in fetal mouse metatarsals in vitro. IL17 may, therefore, participate in the development of cartilage destruction associated with RA by enhancing the effects of TNFα and may provide a potential therapeutic target.Keywords
This publication has 48 references indexed in Scilit:
- PATHWAYS BY WHICH INTERLEUKIN 17 INDUCES ARTICULAR CARTILAGE BREAKDOWN IN VITRO AND IN VIVOCytokine, 2001
- The combination of tumor necrosis factor ? blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo modelArthritis & Rheumatism, 2001
- Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-κB and receptor activator of nuclear factor κB (RANK)/RANK ligand signaling?Bone, 2001
- POTENTIAL CONTRIBUTION OF IL-17- PRODUCING TH1CELLS TO DEFECTIVE REPAIR ACTIVITY IN JOINT INFLAMMATION: PARTIAL CORRECTION WITH Th2-PROMOTING CONDITIONSCytokine, 2001
- Are T cells in rheumatoid synovium aggressors or bystanders?Current Opinion in Rheumatology, 2000
- Interleukin-17: A New Bone Acting Cytokine In VitroJournal of Bone and Mineral Research, 1999
- IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJournal of Clinical Investigation, 1999
- Interleukin-17-induced Gene Expression in Articular Chondrocytes Is Associated with Activation of Mitogen-activated Protein Kinases and NF-κBJournal of Biological Chemistry, 1998
- Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant culturesArthritis & Rheumatism, 1997
- Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption.Journal of Clinical Investigation, 1994